In a study by Dinavahi and others, simultaneously administering capivasertib with the WEE1 inhibitor AZD-1775, synergistically reduced melanoma cell survival in vitro and tumour growth in vivo by driving increased expression of p53 and blocking Akt-mediated activation of FOXM1 (Dinavahi et al., 2018). The gene discussed is TP53; the disease is melanoma.